Cytochrome P450 and Enzyme Interactions

The cytochrome P450 (CYP) enzymes are the principal system metabolizing drugs in the liver and gut, and most clinically important pharmacokinetic drug interactions act through them. When one drug inhibits or induces a CYP enzyme, it changes how fast a co-administered drug is cleared, raising or lowering its exposure and so its effect or toxicity. This topic covers the mechanisms of CYP-mediated interactions and how they are predicted and classified.

Definition

A cytochrome P450 interaction is a pharmacokinetic drug interaction in which one substance inhibits or induces a CYP enzyme, altering the metabolic clearance and therefore the systemic exposure of a co-administered drug that is a substrate of that enzyme.

Scope

The topic covers the major drug-metabolizing CYP isoforms, the distinction between reversible inhibition, mechanism-based (irreversible) inhibition, and enzyme induction, the resulting changes in drug exposure, and how in vitro data are used to predict clinical interactions. It is framed as mechanistic reference knowledge, not as prescribing guidance.

Core questions

• Which CYP isoforms metabolize most marketed drugs, and how is substrate specificity established?
• How do reversible inhibition, mechanism-based inhibition, and induction differ in onset, offset, and magnitude?
• How are clinical interactions predicted from in vitro inhibition and induction data?
• How do genetics and disease alter CYP activity independently of co-medication?

Key concepts

• CYP isoforms (e.g., CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2)
• Substrate, inhibitor, and inducer
• Reversible (competitive) inhibition
• Mechanism-based (irreversible) inhibition
• Enzyme induction
• First-pass metabolism
• In vitro-in vivo extrapolation
• Object (victim) and precipitant (perpetrator) drug

Mechanisms

Cytochrome P450 enzymes oxidize lipophilic drugs to more water-soluble metabolites, chiefly in the liver and intestinal wall. A precipitant drug can inhibit a CYP isoform competitively or, by forming a reactive intermediate, irreversibly (mechanism-based inhibition), reducing the clearance of substrate drugs and raising their concentrations; inhibition of reversible type appears quickly, whereas recovery from mechanism-based inhibition requires synthesis of new enzyme. Conversely, an inducer increases enzyme expression over days, accelerating substrate clearance and lowering exposure, as seen when St John's wort induces CYP3A4 and reduces imatinib exposure. Because many drugs share a few high-traffic isoforms, especially CYP3A4, in vitro measurement of inhibition and induction is used to predict and prioritize which combinations may interact clinically. Disease states such as inflammation can independently suppress CYP activity, adding to genetic variability in enzyme function.

Clinical relevance

CYP-mediated interactions underlie many of the interaction alerts in clinical decision support and the metabolic warnings on drug labels, and understanding them clarifies why a particular combination raises or lowers drug levels. This entry explains the mechanism and classification of such interactions for reference; it does not provide dosing or individualized management advice.

Evidence & guidelines

Mechanistic and pharmacokinetic studies, supported by regulatory in vitro and clinical interaction-study frameworks, form the evidence base for classifying CYP substrates, inhibitors, and inducers. Here that evidence is summarized to explain mechanism rather than to direct therapy.

History

The cytochrome P450 system was characterized biochemically through the mid-twentieth century, and by the 1990s the identification of individual human isoforms and their substrate, inhibitor, and inducer profiles transformed drug-interaction prediction from a reactive, case-report activity into a systematic, mechanism-based part of drug development and clinical pharmacology.

Key figures

• Grant R. Wilkinson
• Larry C. Wienkers
• Edward T. Morgan

Seminal works

• wilkinson-2005
• wienkers-2005

Frequently asked questions

Why is CYP3A4 involved in so many drug interactions?

CYP3A4 is abundant in the liver and intestine and metabolizes a large share of marketed drugs, so inhibiting or inducing it affects the exposure of many substrates simultaneously, making it the single most common locus of metabolic interactions.

What is the difference between enzyme inhibition and induction?

Inhibition reduces enzyme activity and raises substrate drug levels, often rapidly; induction increases enzyme amount over days and lowers substrate levels, with effects that build up and resolve gradually as enzyme is synthesized and then degraded.